Live Chat Support Software
Contact Us
800.227.0627

Cancer - TEW

 
Print Print
Please select subject area:
Cancer
Biosyn
The efficacy of FDA-approved drug inhibiting the ‘cap snatching’ endonuclease of RdRP polymerase is undermined by the emergence of resistant influenza virus strains
04/06/2023
Biosyn
MITO-Porters Enable Delivery of Antisense Drugs to Mitochondria
02/27/2023
Biosyn
Antisense Oligonucleotides as Tracers for PET Imaging
01/31/2023
Biosyn
Affinity-controlled release of 5-fluorouracil by synthetic peptide D-Leu-Phe-Phe-derived hydrogels for the potential treatment of skin cancer
01/27/2023
Biosyn
Kaposi’s sarcoma in immunosuppressed patients due to chemotherapy or transplantation, FDA-approved peptide drug to curb HIV-1 infection, and potential peptide drugs to block COVID-19 infection
12/13/2022
Biosyn
Targeting the amino acid tyrosine of peptides or antibodies for selective bioconjugation of therapeutics
10/27/2022
Biosyn
Writers, Readers, and Erasers of RNA Modifications
09/19/2022
Biosyn
The RNA TrimethylGuanosine or TMG cap
09/08/2022
Biosyn
Development of a therapeutic peptidomimetic inhibiting main protease to reduce the level of RdRP polymerase that replicates COVID-19 coronavirus genome
08/16/2022
Biosyn
FDA approves first digital PCR liquid biopsy test employing oligonucleotide ‘hydrolysis probe’ for monitoring BCR-ABL mRNA in Gleevec or other tyrosine kinase inhibitor treated chronic myelogenous leukemia patients in 2019
07/13/2022
Biosyn
Exploring the efficacy of combination therapy for DNA crosslinking drug mitomycin C (or antimetabolite drug 5-fluorouracil) and the synthetic strategies for crosslinked oligonucleotide duplex
06/14/2022
Biosyn
Strategies for conjugating fluorescent dyes to plasmid DNA to visually track vectors used in gene therapy for cancer or other diseases
05/05/2022
Biosyn
Peptide-drug conjugates being developed to address the side effects issue of FDA-approved antibody-drug conjugates for cancer therapy
03/25/2022
Biosyn
FDA approves first radiopharmaceutical 'peptide-drug conjugate' somatostatin-based OctreoScan for imaging (1994) and LUTATHERA for therapy (2018) of neuroendocrine tumors
02/09/2022
Biosyn
Covid-19 Omicron's impact on humoral and cellular immunity induced by vaccination or antibody-based drugs
01/10/2022
1234567
imgscroll